Peptic Ulcers - Pipeline Review, H1 2017

  • ID: 4311824
  • Report
  • 57 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Astellas Pharma Inc
  • ChoDang Pharm Co Ltd
  • RaQualia Pharma Inc
  • Sequella Inc
  • XuanZhu Pharma Co Ltd
  • MORE
Peptic Ulcers - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Peptic Ulcers - Pipeline Review, H1 2017, provides an overview of the Peptic Ulcers (Gastrointestinal) pipeline landscape.

Peptic ulcers are open sores that develop on the inside lining of esophagus, stomach and the upper portion of small intestine. Symptoms include nausea or vomiting, unexplained weight loss, appetite changes and abdominal pain. Risk factors include smoking and alcoholism. Treatment includes antibiotic, acid blockers, antacids and proton pump inhibitors.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Peptic Ulcers - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Peptic Ulcers (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Peptic Ulcers (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Peptic Ulcers and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 2, 5 and 10 respectively.

Peptic Ulcers (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Peptic Ulcers (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Peptic Ulcers (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Peptic Ulcers (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Peptic Ulcers (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Peptic Ulcers (Gastrointestinal)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Peptic Ulcers (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Peptic Ulcers (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Astellas Pharma Inc
  • ChoDang Pharm Co Ltd
  • RaQualia Pharma Inc
  • Sequella Inc
  • XuanZhu Pharma Co Ltd
  • MORE
  1. Introduction
  2. Peptic Ulcers - Overview
  3. Peptic Ulcers - Therapeutics Development
  4. Pipeline Overview
  5. Pipeline by Companies
  6. Products under Development by Companies
  7. Peptic Ulcers - Therapeutics Assessment
  8. Assessment by Target
  9. Assessment by Mechanism of Action
  10. Assessment by Route of Administration
  11. Assessment by Molecule Type
  12. Peptic Ulcers - Companies Involved in Therapeutics Development
  13. Astellas Pharma Inc
  14. Boryung Pharmaceutical Co Ltd
  15. ChoDang Pharm Co Ltd
  16. Daewoong Pharmaceutical Co Ltd
  17. Kukje Pharmaceutical Industry Co Ltd
  18. RaQualia Pharma Inc
  19. Sequella Inc
  20. Sinil Pharmaceutical Co Ltd
  21. XuanZhu Pharma Co Ltd
  22. Peptic Ulcers - Drug Profiles
  23. (lafutidine + irsogladine maleate) - Drug Profile
  24. Product Description
  25. Mechanism Of Action
  26. R&D Progress
  27. (lansoprazole + omeprazole) - Drug Profile
  28. Product Description
  29. Mechanism Of Action
  30. R&D Progress
  31. anaprazole sodium - Drug Profile
  32. Product Description
  33. Mechanism Of Action
  34. R&D Progress
  35. ASP-6537 - Drug Profile
  36. Product Description
  37. Mechanism Of Action
  38. R&D Progress
  39. BGC-001 - Drug Profile
  40. Product Description
  41. Mechanism Of Action
  42. R&D Progress
  43. cholesteryl glucoside - Drug Profile
  44. Product Description
  45. Mechanism Of Action
  46. R&D Progress
  47. DWJ-1386 - Drug Profile
  48. Product Description
  49. Mechanism Of Action
  50. R&D Progress
  51. DWJ-206 - Drug Profile
  52. Product Description
  53. Mechanism Of Action
  54. R&D Progress
  55. DWP-14012 - Drug Profile
  56. Product Description
  57. Mechanism Of Action
  58. R&D Progress
  59. KJ-14001 - Drug Profile
  60. Product Description
  61. Mechanism Of Action
  62. R&D Progress
  63. PMKS-005 - Drug Profile
  64. Product Description
  65. Mechanism Of Action
  66. R&D Progress
  67. RQ-00000774 - Drug Profile
  68. Product Description
  69. Mechanism Of Action
  70. R&D Progress
  71. SFR-9X0123 - Drug Profile
  72. Product Description
  73. Mechanism Of Action
  74. R&D Progress
  75. SI-001002 - Drug Profile
  76. Product Description
  77. Mechanism Of Action
  78. R&D Progress
  79. Small Molecule to Inhibit Potassium Transporting ATPase Alpha Chain 1 Inhibitor for Peptic Ulcers and Reflux Esophagitis - Drug Profile
  80. Product Description
  81. Mechanism Of Action
  82. R&D Progress
  83. Small Molecules for Gastric Ulcers - Drug Profile
  84. Product Description
  85. Mechanism Of Action
  86. R&D Progress
  87. SQ-109 - Drug Profile
  88. Product Description
  89. Mechanism Of Action
  90. R&D Progress
  91. tegoprazan - Drug Profile
  92. Product Description
  93. Mechanism Of Action
  94. R&D Progress
  95. Peptic Ulcers - Dormant Projects
  96. Peptic Ulcers - Discontinued Products
  97. Peptic Ulcers - Product Development Milestones
  98. Featured News & Press Releases
  99. Jul 17, 2013: Sihuan Pharmaceutical Secures SFDA Approval for Anaprazole Sodium Category 1.1 New Drug Clinical Studies
  100. Dec 06, 2010: Sequella Wins FDA Approval To Begin Phase II Trial Of SQ109 In Helicobacter pylori-Associated Duodenal Ulcers
  101. Mar 01, 2010: AstraZeneca Provides An Update On The Status Of Its Arrangements With Merck
  102. Mar 01, 2010: AstraZeneca Provides An Update On The Status Of Its Arrangements With Merck
  103. Jan 07, 2010: AstraZeneca Reaches Agreements With Teva Pharmaceuticals Regarding Nexium And Prilosec US Patent Litigations
  104. Jan 07, 2010: AstraZeneca Reaches Agreements With Teva Pharmaceuticals Regarding Nexium And Prilosec US Patent Litigations
  105. Apr 15, 2008: AstraZeneca Settles US Nexium Patent Litigation with Ranbaxy
  106. Apr 15, 2008: AstraZeneca Settles US Nexium Patent Litigation with Ranbaxy
  107. Feb 28, 2008: AstraZeneca Provides An Update on the Status of its Arrangements With Merck & Co., Inc.
  108. Feb 28, 2008: AstraZeneca Provides An Update on the Status of its Arrangements With Merck & Co., Inc.
  109. Dec 10, 2007: FDA Concludes There Is No Increased Risk Of Cardiac Events For Patients Treated With Omeprazole And NEXIUM (Esomeprazole Magnesium)
  110. Dec 10, 2007: FDA Concludes There Is No Increased Risk Of Cardiac Events For Patients Treated With Omeprazole And NEXIUM (Esomeprazole Magnesium)
  111. Jun 01, 2007: AstraZeneca’s Prilosec Patents Upheld By Court
  112. Jun 01, 2007: AstraZeneca’s Prilosec Patents Upheld By Court
  113. Dec 12, 2003: Astrazeneca Prilosec Patents Upheld by Federal Appeals Court
  114. Appendix
  115. Methodology
  116. Coverage
  117. Secondary Research
  118. Primary Research
  119. Expert Panel Validation
  120. Contact Us
  121. Disclaimer
List of Tables:
  1. Number of Products under Development for Peptic Ulcers, H1
  2. Number of Products under Development by Companies, H1
  3. Products under Development by Companies, H1
  4. Number of Products by Stage and Target, H1
  5. Number of Products by Stage and Mechanism of Action, H1
  6. Number of Products by Stage and Route of Administration, H1
  7. Number of Products by Stage and Molecule Type, H1
  8. Peptic Ulcers - Pipeline by Astellas Pharma Inc, H1
  9. Peptic Ulcers - Pipeline by Boryung Pharmaceutical Co Ltd, H1
  10. Peptic Ulcers - Pipeline by ChoDang Pharm Co Ltd, H1
  11. Peptic Ulcers - Pipeline by Daewoong Pharmaceutical Co Ltd, H1
  12. Peptic Ulcers - Pipeline by Kukje Pharmaceutical Industry Co Ltd, H1
  13. Peptic Ulcers - Pipeline by RaQualia Pharma Inc, H1
  14. Peptic Ulcers - Pipeline by Sequella Inc, H1
  15. Peptic Ulcers - Pipeline by Sinil Pharmaceutical Co Ltd, H1
  16. Peptic Ulcers - Pipeline by XuanZhu Pharma Co Ltd, H1
  17. Peptic Ulcers - Dormant Projects, H1
  18. Peptic Ulcers - Dormant Projects, H1 2017 (Contd..1), H1
  19. Peptic Ulcers - Discontinued Products, H1
List of Figures:
  1. Number of Products under Development for Peptic Ulcers, H1
  2. Number of Products under Development by Companies, H1
  3. Number of Products by Top 10 Targets, H1
  4. Number of Products by Stage and Top 10 Targets, H1
  5. Number of Products by Mechanism of Actions, H1
  6. Number of Products by Stage and Top 10 Mechanism of Actions, H1
  7. Number of Products by Stage and Routes of Administration, H1
  8. Number of Products by Molecule Types, H1
  9. Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Astellas Pharma Inc
  • Boryung Pharmaceutical Co Ltd
  • ChoDang Pharm Co Ltd
  • Daewoong Pharmaceutical Co Ltd
  • Kukje Pharmaceutical Industry Co Ltd
  • RaQualia Pharma Inc
  • Sequella Inc
  • Sinil Pharmaceutical Co Ltd
  • XuanZhu Pharma Co Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll